Acceder

Bibliografías temáticas / Neovascularisation / Artículos de revistas

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Neovascularisation.

Artículos de revistas sobre el tema "Neovascularisation"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 29 de marzo de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Neovascularisation".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Nazm, Nazneen, Nadeem y Madhura Mukherjee. "To study the extent of regression of retinal neovascularisation in proliferative diabetic retinopathy following laser photocoagulation of the ischaemic retina". Indian Journal of Clinical and Experimental Ophthalmology 11, n.º 1 (15 de febrero de 2025): 24–30. https://doi.org/10.18231/j.ijceo.2025.005.

Texto completo

Resumen

Eyes with proliferative diabetic retinopathy have a variable response to treatment with panretinal photocoagulation (PRP) or anti–vascular endothelial growth factor agents. We undertook this study to find out what is the exact extent of regression of neovascularisation with PRP and what are the factors that correlate with this variation in response. Present Prospective Study was conducted in Subjects with Proliferative Diabetic Retinopathy attending the ophthalmology department at ESI-PGIMSR and Model Hospital, Basaidarapur, New Delhi from October 2019-April 2021. During the above-mentioned period a total of 38 eyes of 22 patients with proliferative diabetic retinopathy were selected for the study. This study was done to evaluate the regression of neovascularisation after panretinal photocoagulation for proliferative diabetic retinopathy. In our study population, 16 (72.72%) of the subjects were males with age (mean ± SD) 60.00± 4.20 years were more than females 6 (27.27%) with age (mean ± SD) 51.56± 5.41 years. the area of neovascularisation in our patients ranged from 0.42 mm2 to 9.23 mm2 while the area of NVD in our patients ranged from 0 mm2 to 0.8 mm2 and the area of NVE in our patients at baseline ranged from 0.21 mm2 to 8.61 mm2. After 3 months of PRP all the neovascularisations showed regression to a significant extent. 31.58% of PDR eyes shows complete neovascularisation regression while 68.42% shows partial regression which is highly significant. PRP was shown to induce regression of neovascularisation and arrest of progression of diabetic retinopathy. PRP in PDR reduced the risk of severe visual loss. Timely applied laser photocoagulation of the ischaemic retina was effective in causing regression of the already developed neovascularisation and in preventing further development of neovascularisation.

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Creton, D. "Neovascularisation". Phlebologie 37, n.º 03 (mayo de 2008): 134–41. http://dx.doi.org/10.1055/s-0037-1622223.

Texto completo

Resumen

SummaryThere are different causes of neovascularisation: vascular endothelial growth factor, inflammatory process, hypertrophy of pre-existant vessels (lymph node veins), haematomas revascularisation, and high difference in pressure. The latter 3 depend directly on the way the operation is performed hence on the surgeon.Concerning the primary varices patch saphenoplasty do not abolish neovascularisation. It is of first importance to perform a flush ligation only in case of incontinent terminal and pre-terminal valves. In that case an incision as small as possible must be carried out with minimal dissection and with tumescence to limit the bleeding and hematomas. When the terminal valve is competent it is better to choose endovascular technique.Concerning re-do it is mandatory to avoid useless re-do, the best choice is foam sclerotherapy. I am convinced that neovascularisation are produced by the complications which are induced by a large dissection. The barrier technique are, probably, not as useful as we was told 10 years ago. The lack of aggressiveness during the operation is certainly far more important: “Doing less in the groin to do better for the recurrence and re-recurrence”

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Holmgren, L. "Malignant Neovascularisation". European Journal of Ultrasound 6 (noviembre de 1997): S11. http://dx.doi.org/10.1016/s0929-8266(97)87215-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Smith, R. "Neovascularisation again." British Journal of Ophthalmology 74, n.º 6 (1 de junio de 1990): 323. http://dx.doi.org/10.1136/bjo.74.6.323.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Badal, Josep, Luis Amselem, Ricardo Aleman y Frederic Huste. "Anti–vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularisation". European Ophthalmic Review 07, n.º 02 (2013): 84. http://dx.doi.org/10.17925/eor.2013.07.02.84.

Texto completo

Resumen

Pathological myopia represents the most common cause of choroidal neovascularisation in young patients. Its natural course has a devastating prognosis. Several treatments have been assessed, but photodynamic therapy is currently the only approved treatment for subfoveal choroidal neovascularisation related to pathological myopia. Anti-vascular endothelial growth factor therapy has demonstrated promising results in any form and localisation of choroidal neovascularisation, although there is an absence of data obtained from randomised clinical trials. The aim of this article is to compare different treatment options, combinations and retreatment criteria for the management of choroidal neovascularisation in eyes with high myopia.

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Shehadeh, Mohammad M., Mohammad T. Akkawi, Vasilios F. Diakonis, Ammar A. Aghbar y Abdelraheem Abu Shanab. "Extensive Corneal Neovascularisation Treatment by Ultraviolet Corneal Collagen Crosslinking". European Ophthalmic Review 11, n.º 01 (2017): 62. http://dx.doi.org/10.17925/eor.2017.11.01.62.

Texto completo

Resumen

The purpose of this article is to report a case of extensive corneal neovascularisation that was treated by ultraviolet corneal collagen crosslinking (CXL). The case report is about a 24-year-old man who was referred to the cornea clinic with a case of keratitis. He was treated with topical antibiotics. After full resolution of keratitis, his condition was complicated by extensive corneal neovascularisation. A trial of photochemical corneal collagen CXL with riboflavin/ultraviolet A resulted in a dramatic improvement and resolution of the corneal neovascularisation. Thus, we can conclude that corneal collagen CXL could be a promising procedure to treat certain cases of extensive corneal neovascularisation.

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Imre, G. "Lactic acid neovascularisation." British Journal of Ophthalmology 75, n.º 4 (1 de abril de 1991): 254. http://dx.doi.org/10.1136/bjo.75.4.254.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Chan, Elsie, Jennifer Fan Gaskin y Elsa C. Chan. "Corneal Neovascularisation and Anti-VEGF Therapy". Targets 3, n.º 1 (10 de marzo de 2025): 9. https://doi.org/10.3390/targets3010009.

Texto completo

Resumen

Cornea vascularisation is a significant cause of ocular morbidity. Disease or injury often triggers the development of new blood vessels in the cornea, compromising its clarity and impairing vision. Common causes of corneal neovascularisation include infections, chemical burns, and local and systemic inflammatory disorders. Topical corticosteroid eye drops remain the standard therapy; however, extended use of corticosteroids has been known to cause side-effects including cataracts and raised intraocular pressure. As such, an alternative therapy has been actively sought. Vascular endothelial growth factor (VEGF) is a major angiogenic factor implicated in neovascularisation. The success of anti-VEGF agents in managing leaking blood vessels in neovascular age-related macular degeneration provides an opportunity to explore its use in the treatment of corneal neovascularisation. The therapeutic potential of anti-VEGF agents has been evaluated in experimental models of corneal neovascularisation and clinical trials with variable results. Here, we review the study results and discuss the development of new strategies that may improve treatment outcomes for corneal neovascularisation.

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Cheng, Jacob YC, Doric WK Wong y Chong Lye Ang. "Intraocular Avastin (Bevacizumab) for Neovascularisation of the Iris and Neovascular Glaucoma". Annals of the Academy of Medicine, Singapore 37, n.º 1 (15 de enero de 2008): 72–74. http://dx.doi.org/10.47102/annals-acadmedsg.v37n1p72.

Texto completo

Resumen

Introduction: The aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma. Clinical Picture: Three patients with neovascularisation of the iris due to various causes were recruited. Treatment: Patients were treated with intraocular bevacizumab. Outcome: Neovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients’ eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed. Conclusion: Intraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage. Key words: Intravitreal, Vascular endothelial growth factor, Vitreous haemorrhage

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Buragohain, Suklengmung, Harsha Bhattacharjee y Henal Javeri. "Capsular neovascularisation in uveitis". Indian Journal of Ophthalmology - Case Reports 1, n.º 3 (2021): 458. http://dx.doi.org/10.4103/ijo.ijo_3625_20.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Faraj, L. A., D. G. Said y H. S. Dua. "Evaluation of corneal neovascularisation". British Journal of Ophthalmology 95, n.º 10 (21 de septiembre de 2011): 1343–44. http://dx.doi.org/10.1136/bjophthalmol-2011-300856.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Stavrou, D. "Neovascularisation in wound healing". Journal of Wound Care 17, n.º 7 (julio de 2008): 298–302. http://dx.doi.org/10.12968/jowc.2008.17.7.30521.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Sunness, J. S. "Choroidal neovascularisation and atrophy". British Journal of Ophthalmology 90, n.º 4 (1 de abril de 2006): 398–99. http://dx.doi.org/10.1136/bjo.2005.084830.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Sivaprasad, S. y A. T. Moore. "Choroidal neovascularisation in children". British Journal of Ophthalmology 92, n.º 4 (27 de marzo de 2008): 451–54. http://dx.doi.org/10.1136/bjo.2007.124586.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Binns, Malcolm y Robert W. H. Pho. "Neovascularisation of the epiphysis". Microsurgery 12, n.º 1 (1991): 9–13. http://dx.doi.org/10.1002/micr.1920120103.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Carrozzo, Alessandro, Jobe Shatrov, Abdo El Helou, Francesco Pettinari, Ali Alayane, Ahmad Abed Ali, Julien Clechet, Thais Dutra Vieira y Bertrand Sonnery-Cottet. "Ultrasound-guided electrocoagulation of neovascularisation for persistent patellar tendinopathy in athletes: a cohort study of 25 patients with a mean follow-up of 5 years from the SANTI Study Group". BMJ Open Sport & Exercise Medicine 10, n.º 1 (marzo de 2024): e001900. http://dx.doi.org/10.1136/bmjsem-2024-001900.

Texto completo

Resumen

BackgroundPatellar tendinopathy (PT) is a common condition characterised by persistent patellar tendon pain and dysfunction, particularly in athletes. Neovascularisation is frequently observed in the PT and is associated with increased pain. Ultrasound-guided electrocoagulation of neovascularisation has emerged as a minimally invasive alternative treatment for recalcitrant PT.Hypothesis/purposeThe purpose of this study was to evaluate the clinical outcomes of ultrasound-guided electrocoagulation of neovascularisation in athletes with persistent PT.Study designCase series; level of evidence, IV.MethodsA retrospective analysis of prospectively collected data was performed on 25 athletes who underwent ultrasound-guided electrocoagulation of neovascularisation for recalcitrant PT. Clinical outcomes including complications, reinterventions and patient-reported outcome measures were recorded. Comparisons between variables were assessed using χ2test or Fisher’s exact test for categorical variables and Student’s t-test or Wilcoxon test for quantitative variables.Results25 patients were included in the final analysis. 96% returned to their preoperative activity level at a mean of 3.8 months. At a mean follow-up of 5 years 4% did not receive significant benefit from electrocoagulation therapy. Significant improvements were observed in outcome measures, including the Victorian Institute of Sport Assessment Questionnaire for Patients with Patellar Tendinopathy, Kujala score, modified Blazina score and Visual Analogue Scale for pain.ConclusionUltrasound-guided electrocoagulation of neovascularisation for persistent PT in elite athletes resulted in a low complication rate, a high rate and rapid return to sport and a significant improvement in outcome measures.

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Wali, Keerti, Shilpa Maled, Ronak Solanki, Apoorva G. Ayachit y Aniket N. Shastri. "Safety and efficacy of frequency-doubled Nd-YAG laser photocoagulation of different types of corneal neovascularisation (NLPC): a prospective study". BMJ Open Ophthalmology 10, n.º 1 (marzo de 2025): e001734. https://doi.org/10.1136/bmjophth-2024-001734.

Texto completo

Resumen

PurposeFrequency doubling of neodymium-doped yttrium aluminum garnet (Nd-YAG) laser results in emission of photocoagulating 532 nm light compared with photolytic 1064 nm emission. The ergonomic benefits of solid-state lasers led to replacement of older coagulating lasers in ophthalmic centres by frequency-doubled Nd-YAG laser. Our study aims to evaluate safety and efficacy of frequency-doubled Nd-YAG laser for photocoagulation of corneal neovascularisation (NLPC).Methods30 quiet eyes of 28 patients with superficial, mid-stromal and deep stromal inactive corneal neovascularisation were subjected to laser photocoagulation. Resolution of vessels, procedural complications and survival of subsequent corneal grafts were monitored for 3 months. Anterior segment fluorescein angiography (AS-FA) was performed in six eyes to confirm the cessation of blood flow.Results20 eyes (66.66%) had complete resolution of neovascularisation. 13 cases of superficial (92.86%) and 6 cases of mid-stromal neovascularisation (75%) showed significant resolution, compared with 1 case of deep neovascularisation (12.5%). Minimal corneal burn (n=4, 13.33%), iris holes (n=3, 10%), anterior chamber bubbles (n=5, 16.67%), self-resolving intrastromal bleed (n=2, 6.67%) and graft-host junctional wound leak (n=1 of 12 keratoplasty cases, 8.33%) were noted.ConclusionNLPC may especially be useful in the eyes with a large vessel arborising within stroma. Lack of comparison with other treatment options leading to inflated safety and efficacy profile of NLPC is the major limitation of this study.

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Bobryshev, Y. V., A. E. Farnsworth y R. S. A. Lord. "Expression of Vascular Endothelial Growth Factor in Aortocoronary Saphenous Vein Bypass Grafts". Cardiovascular Surgery 9, n.º 5 (octubre de 2001): 492–98. http://dx.doi.org/10.1177/096721090100900515.

Texto completo

Resumen

Neovascularisation is a prominent feature of long-term aortocoronary saphenous vein bypass grafts but mechanisms involved in the formation of neovessels have not been previously studied. Vascular Endothelial Growth Factor (VEGF) is an important angiogenic factor that induces migration and proliferation of endothelial cells, enhances permeability and modulates thrombogenecity. This study investigated the expression of VEGF in aortocoronary saphenous vein bypass grafts. Aortocoronary saphenous vein bypass grafts with angiographic luminal stenosis of >75% were explanted from 14 patients at redo coronary artery bypass grafting. The grafts demonstrated two distinct forms of graft occlusion: four out of the 14 graft occlusions (29%) resulted from severe hyperplastic transformation of the intima complicated by thrombi attached to the degenerating liminal endothelium; the remaining graft occlusions (71%) were due to the development of atherosclerotic lesions associated with mural thrombosis. Hiperplastically altered intimal segments were practically free of neovascularisation while atherosclerotic-like lesions contained neovessels irregularly distributed throughout. Intimal neovessels were located exclusively in microzones enriched with VEGF-expressing cells and, furthermore, neovascular endothelial cells themselves also displayed VEGF immunopositivity. Double-immunostaining revealed that in areas of neovascularisation, the vast majority macrophages (CD68+) expressed VEGF. Some CD68+ foam cells that surrounded branches of neovascularisation were also VEGF-positive. These findings suggest that VEGF expressed by neovascular endothelial cells and by macrophages may act as a local regulator of endothelial cells functions and may induce intimal neovascularisation in aortocoronary saphenous vein bypass grafts affected by atherosclerosis.

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Bainbridge, James W., Vanya Loroch, Eric Viaud y Claus Cursiefen. "Beyond Anti-VEGFs – Anti-Insulin Receptor Substrate-1 Oligonucleotides as a Novel Approach to Ocular Neovascular Disorders". European Ophthalmic Review 06, n.º 03 (2012): 190. http://dx.doi.org/10.17925/eor.2012.06.03.190.

Texto completo

Resumen

Angiogenesis is a complex process that is vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. For optimal efficacy and safety, therapies aimed at preventing angiogenic-mediated disorders must differentiate between healthy and pathological angiogenesis or neovascularisation. Aganirsen is an antisense oligonucleotide that inhibits the insulin receptor substrate (IRS)-1 angiogenic pathway by targeting the IRS-1 messenger RNA. To date, studies of aganirsen have focused mainly on ocular disorders because of the ability to assess non-invasively the effect of the drug on neovascularisation and to address the unmet need for effective therapies in these blinding disorders. Aganirsen (GS-101) eye drops inhibit progressive corneal neovascularisation and appear to be well tolerated. The drug may offer an alternative and/or adjunct to intraocular anti-vascular endothelial cell growth factor (VEGF) agents, which are the current reference standards to prevent neovascularisation in retinal diseases. This is because it has a different and potentially complementary mechanism of action and can be administered topically. Antisense oligonucleotides targeting IRS-1 may present a valuable new approach to control pathological angiogenesis in the eye and elsewhere.

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Diamond, Michael Adam, Sze Wah Samuel Chan, Xun Zhou, Yelena Glinka, Eileen Girard, Yeni Yucel y Neeru Gupta. "Lymphatic vessels identified in failed corneal transplants with neovascularisation". British Journal of Ophthalmology 103, n.º 3 (22 de octubre de 2018): 421–27. http://dx.doi.org/10.1136/bjophthalmol-2018-312630.

Texto completo

Resumen

BackgroundCorneal transplant failure with neovascularisation is a leading indication for full-thickness grafts in patients. Lymphangiogenesis is implicated in the pathology of graft failure, and here we systematically evaluate failed human corneal transplants with neovascularisation for the presence of lymphatic vessels.MethodsNine failed grafts with neovascularisation, based on H&E staining with subsequent immunoperoxidase staining for CD31, a blood vessel marker, were selected. Lymphatics were investigated by immunohistochemical and immunofluorescence approaches using podoplanin as a lymphatic marker. In two of nine cases, fluorescence in situ hybridisation (FISH) was used for detection of lymphatic mRNAs including podoplanin, VEGFR-3 and LYVE-1. All immunofluorescence and FISH samples were compared with positive and negative controls and visualised by confocal microscopy.ResultsCorneal neovascularisation was established in all cases by H&E and further confirmed by CD31 immunoreactive profiles. Immunohistochemistry for the podoplanin antibody was positive in all cases and showed morphologies ranging from distinct luminal structures to elongated profiles. Simultaneous immunofluorescence using CD31 and podoplanin showed lymphatic vessels distinct from blood vessels. Podoplanin immunofluorescence was noted in seven of nine cases and revealed clear lumina of varying sizes, in addition to lumen-like and elongated profiles. The presence of lymphatic mRNA was confirmed by FISH studies using a combination of at least two of podoplanin, VEGFR-3 and LYVE-1 mRNAs.ConclusionsThe consistent finding of lymphatic vessels in failed grafts with neovascularisation implicates them in the pathogenesis of corneal transplant failure, and points to the lymphatics as a potential new therapeutic target.

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Oki, Aqsa Sjuhada, Moch Febi Alviansyah, Christian Khoswanto, Retno Pudji Rahayu y Muhammad Luthfi. "Acceleration of post-tooth extraction socket healing after continuous aerobic and anaerobic physical exercise in Wistar rats (Rattus norvegicus)". Dental Journal (Majalah Kedokteran Gigi) 53, n.º 4 (24 de noviembre de 2020): 196. http://dx.doi.org/10.20473/j.djmkg.v53.i4.p196-200.

Texto completo

Resumen

Background: Physical exercise has been proven to accelerate wound healing. Physical training itself consists of aerobic (continuous training) and anaerobic (interval training) exercise. The effectiveness of continuous physical exercise on post-tooth extraction wound healing is the focus of this study. Purpose: This study aims to investigate the differences in post-tooth extraction wound healing in Wistar rats (Rattus norvegicus) after aerobic and anaerobic exercise based on the number of fibroblasts and neovascularisation. Methods: Wistar rats were divided into three groups: the control group (K1); K2 undertook continuous aerobic exercise, swimming at 50% maximum swimming capacity (MSC) with an additional 3% bodyweight load; K3 undertook anaerobic continuous exercise, swimming at 65% MSC with a 6% load. The rats swam three times per week for six weeks. The number of fibroblasts and neovascularisation were examined three days after tooth extraction. Data was analysed using the one-way analysis of variance (ANOVA) and Least Significant Difference (LSD) tests (p<0.05). Results: There was a significant difference in the number of fibroblasts between the K2 and K3 groups. There was no significant difference between K2 and K3 in the amount of neovascularisation. Conclusion: There were differences in the number of fibroblasts but not neovascularisation after tooth extraction in Wistar rats given aerobic and anaerobic continuous training.

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Holló, Gábor. "Diabetic neovascularisation and secondary glaucoma". Orvosi Hetilap 152, n.º 29 (julio de 2011): 1167–70. http://dx.doi.org/10.1556/oh.2011.29042.

Texto completo

Resumen

Neovascular glaucoma develops from intraocular neovascularisation in diabetes mellitus. Neovascularisation is a consequence of hypoxia-induced production of vascular endothelial growth factor-A. Neovascular glaucoma is one of the most serious, sight-threatening late complications of diabetes. Several intraocular pressure lowering drugs, surgical and adjunctive laser treatments have been used to treat this disease, but the efficacy of the interventions is limited. The role of vascular endothelial growth factor-A blocking therapy in the treatment of neovascular glaucoma remains to be determined. Development of neovascularisation, however, can be prevented with adequate long-term glycemic and lipid control, effective treatment of arterial hypertension and optimal timing of adequate panretinal photocoagulation, in the majority of the cases. Unfortunately, in clinical practice diabetic neovascular glaucoma is more frequently experienced in Hungary than would be expected based on the variety of available therapeutic possibilities. In order to increase the success of prevention both cooperation of general practitioners, diabetologists, dietitians and ophthalmologists, and compliance of diabetic patients need to be improved. Orv. Hetil., 2011, 152, 1167–1170.

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Augustin, Albert J. y Indre Offermann. "Combination Therapy for Choroidal Neovascularisation". Drugs & Aging 24, n.º 12 (2007): 979–90. http://dx.doi.org/10.2165/00002512-200724120-00002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Cheung, C. M. G., O. M. Durrani y P. Stavrou. "Peripapillary choroidal neovascularisation in sarcoidosis". Ocular Immunology and Inflammation 10, n.º 1 (enero de 2002): 69–73. http://dx.doi.org/10.1076/ocii.10.1.69.10324.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Groeneveld, Erwin y Paul Eliadis. "Interferon for subfoveal choroidal neovascularisation". Australian and New Zealand Journal of Ophthalmology 21, n.º 2 (mayo de 1993): 133–34. http://dx.doi.org/10.1111/j.1442-9071.1993.tb00769.x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Kaplan, H. "Submacular surgery for choroidal neovascularisation." British Journal of Ophthalmology 80, n.º 2 (1 de febrero de 1996): 101. http://dx.doi.org/10.1136/bjo.80.2.101.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Lee, M. S. "Choroidal neovascularisation associated with meningioma". British Journal of Ophthalmology 89, n.º 10 (1 de octubre de 2005): 1384–85. http://dx.doi.org/10.1136/bjo.2005.071696.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Postelmans, L., P. Coquelet, C. Verougstraete y F. Willermain. "Treatment of peripapillary choroidal neovascularisation". British Journal of Ophthalmology 92, n.º 5 (25 de abril de 2008): 721–22. http://dx.doi.org/10.1136/bjo.2007.135095.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Yip, Vivien C., Leonard W. Yip y Augustinus Laude. "Subconjunctival bevacizumab for iris neovascularisation". Lancet Diabetes & Endocrinology 2, n.º 6 (junio de 2014): 449–50. http://dx.doi.org/10.1016/s2213-8587(14)70070-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Cann, StephenA, JohannesP van Netten, TearaL Ashby, MichaelJ Ashwood-Smith y NicholasG van der Westhuizen. "Role of lymphagenesis in neovascularisation". Lancet 346, n.º 8979 (septiembre de 1995): 903. http://dx.doi.org/10.1016/s0140-6736(95)92744-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Rowson, Neil J., John K. G. Dart y Roger J. Buckley. "Corneal neovascularisation in acute hydrops". Eye 6, n.º 4 (julio de 1992): 404–6. http://dx.doi.org/10.1038/eye.1992.83.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Graham, E. M., M. R. Stanford, J. S. Shilling y M. D. Sanders. "Neovascularisation associated with posterior uveitis." British Journal of Ophthalmology 71, n.º 11 (1 de noviembre de 1987): 826–33. http://dx.doi.org/10.1136/bjo.71.11.826.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Ohnishi, Yoshitaka, Tatsuro Ishibashi y Takuji Sagawa. "Fluorescein gonioangiography in diabetic neovascularisation". Graefe's Archive for Clinical and Experimental Ophthalmology 232, n.º 4 (abril de 1994): 199–204. http://dx.doi.org/10.1007/bf00184005.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Hummel, T., P. Burger, N. Frings, M. Hartmann, M. Broermann, C. Schwahn-Schreiber, D. Stenger, M. Stücker y A. Mumme. "High ligation of the saphenofemoral junction is necessary!" Phlebologie 38, n.º 03 (2009): 99–102. http://dx.doi.org/10.1055/s-0037-1622261.

Texto completo

Resumen

SummaryNeovascularisation can compromise the success of high ligation and resection of the greater saphenous vein. Studies using duplexultrasound to classify recurrent groin veins have described rates of neovascularisation as high as 60% and raised the question whether high ligation is actually able to prevent groin recurrences. In the present study, recurrent groin veins were excised and examined histologically in order to prove whether neovascularisation is the main cause for sapheno-femoral recurrences. Patients, methods: 419 patients accounting for 458 legs with clinically symptomatic groin recurrences were included in a country-wide multicenter study. The recurrent groin veins were excised in a standardized fashion and subsequently divided into the different types of recurrence based on histopathological criteria. Results: 427 specimen (93%) were available for histopathological examination. In 69 cases (16.2%) a neovascularisation was found to be the cause of recurrence. 311 specimen (72.8%) contained a long residual stump of the greater saphenous vein, out of which 32 (7.5%) showed additional neovascularisation at the site of the ligation. In 29 cases (6.8%) a venous side branch was found to be the recurrent groin vein. 11 specimen (2.6%) did not contain any evidence of venous material and in another 7 cases (1.6%) it was not possible to clearly identify the cause of recurrence during the histo pathological workup. Conclusion: The high rates of neovascularisation described in several duplex ultrasound studies could not be confirmed in our investigation. Recurrences seem to be mainly caused by a technically incorrect initial operation which leaves a long residual stump of the saphenous vein in place. Following a technically correct high ligation, clinically relevant recurrences appear to be rare. This finding underlines the necessity of a high ligation of the saphenous vein according to current guidelines.

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

De Maeseneer, M. G., I. F. Tielliu, P. E. Van Schil, S. G. De Hert y E. J. Eyskens. "Clinical Relevance of Neovascularisation on Duplex Ultrasound in the Long-Term Follow-up after Varicose Vein Operation". Phlebology: The Journal of Venous Disease 14, n.º 3 (septiembre de 1999): 118–22. http://dx.doi.org/10.1177/026835559901400306.

Texto completo

Resumen

Objective: To evaluate the clinical relevance of neovascularisation at the saphenous ligation site. Design: Long-term follow-up after previous varicose vein surgery in a single patient group. Setting: Vascular clinic of a university hospital. Patients: Eighty-two patients (106 limbs) with a mean follow-up period of 56 months after correct saphenous ligation were submitted to duplex scanning. Intervention: Clinical assessment and colour duplex scanning of all the operated limbs. Reintervention in 15 limbs with perioperative evaluation of recurrent veins. Main outcome measures: Limbs with and without recurrent varicose veins were classified according to the degree of neovascularisation: grade 0 = no new communicating veins, grade 1 = tiny new vein with diameter <4 mm, grade 2 = new communicating vein with diameter >4 mm and pathological reflux. On reintervention the presence of neovascular veins at the site of the previous ligation was checked. Results: In 68 limbs without recurrent varicose veins, grade 0 was observed in 50 limbs (74%), grade 1 in 12 limbs (18%) and grade 2 in six limbs (9%). In 38 limbs with recurrent varicose veins, grade 0 was diagnosed in eight limbs (21%), grade 1 in four limbs (11%) and grade 2 in 26 limbs (68%). In 15 limbs with recurrent varicose veins and grade 2 neovascularisation, reintervention confirmed the duplex findings. Conclusions: The presence of grade 2 neovascularisation was associated with the recurrence of varicose veins, suggesting a causal relationship.

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Haj Najeeb, Bilal, Gabor G. Deak, Ursula Margarethe Schmidt-Erfurth y Bianca S. Gerendas. "RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3". British Journal of Ophthalmology 105, n.º 1 (11 de marzo de 2020): 113–17. http://dx.doi.org/10.1136/bjophthalmol-2019-315311.

Texto completo

Resumen

PurposeTo report on patients with macular neovascularisation type III (MNV3) arising from cilioretinal arteries (CRAs) (cilioretinal macular neovascularisation type III (cMNV3)).MethodsWe reviewed baseline examinations of patients with neovascular age-related macular degeneration using multimodal imaging. We determined the type and distribution of MNV lesions in each cMNV3 case, the range of distances from the fovea, existence of exudative maculopathy, intraretinal haemorrhage and other morphological characteristics. 50 consecutive eyes with usual MNV3 without CRA were included as a control group.Results102 eyes of 102 patients were identified with MNV3 lesions. Among these, we found 12 eyes (12%) with cMNV3, 84 eyes (82%) with usual MNV3 without CRA and 6 eyes (6%) with usual MNV3 with CRA. Ten cases of cMNV3 had one lesion, and two cases had two lesions. The lesions were distributed equally between the superior and inferior halves of the macula, whereas in the nasal and temporal halves, there were 8 (57%) and 6 (43%) lesions, respectively. All cMNV3 lesions were located between 500 and 1500 µm from the central fovea except one, which was located between 1500 and 3000 µm. None of the lesions had macular neovascularisation type I (MNV1) or macular neovascularisation type II (MNV2) elsewhere in both groups. Exudative maculopathy and intraretinal haemorrhage were found in seven (88%) and five (63%) of the eight pure cMNV3 cases, respectively.ConclusioncMNV3 can be solitary or multiple, isolated or accompanied with usual MNV3 lesions, but not with concurrent MNV1 or MNV2. It is frequently associated with extensive exudative maculopathy, intraretinal haemorrhage and subretinal fluid.

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Dervenis, Nikolaos, Panagiotis Dervenis y Eleftherios Agorogiannis. "Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review". BMJ Open Ophthalmology 9, n.º 1 (febrero de 2024): e001516. http://dx.doi.org/10.1136/bmjophth-2023-001516.

Texto completo

Resumen

Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current therapeutic options. Neovascularisation development during the course of the disease has a complex pathogenetic mechanism, and several biomarkers and their association with treatment outcomes have been investigated. We reviewed the relevant literature about neovascularisation development and biomarkers related to response to treatment. Improving our knowledge on the field can improve patient outcomes and offer personalised care.

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

&NA;. "Changing times for intraocular neovascularisation, oedema". Inpharma Weekly &NA;, n.º 1654 (septiembre de 2008): 9. http://dx.doi.org/10.2165/00128413-200816540-00015.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Tuncel, Alper, Merdan Serin y Mehmet Bayramicli. "Venous component in scar penetrating neovascularisation". Journal of Plastic Surgery and Hand Surgery 52, n.º 1 (9 de mayo de 2017): 47–52. http://dx.doi.org/10.1080/2000656x.2017.1319848.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Lee, D. K. "Serpiginous choroidopathy presenting as choroidal neovascularisation". British Journal of Ophthalmology 87, n.º 9 (1 de septiembre de 2003): 1184–85. http://dx.doi.org/10.1136/bjo.87.9.1184.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Berger, Lisa y Bernhard M. Stoffelns. "Photodynamic Therapy in Subfoveal Choroidal Neovascularisation". Medical Laser Application 17, n.º 4 (enero de 2002): 331–40. http://dx.doi.org/10.1078/1615-1615-00078.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

AI-Husainy, S., P. Stavrou y M. W. Hope-Ross. "Alkali injury complicated by choroidal neovascularisation". Eye 14, n.º 6 (noviembre de 2000): 904–5. http://dx.doi.org/10.1038/eye.2000.247.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Mehta, J. S., A. S. Jacks, V. Maurino y A. M. P. Hamilton. "Neovascularisation in a patent chorioretinal anastomosis". Eye 14, n.º 6 (noviembre de 2000): 916–18. http://dx.doi.org/10.1038/eye.2000.256.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Menzel-Severing, J. "Emerging techniques to treat corneal neovascularisation". Eye 26, n.º 1 (7 de octubre de 2011): 2–12. http://dx.doi.org/10.1038/eye.2011.246.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

McLEOD, D. "Entry site neovascularisation after diabetic vitrectomy". British Journal of Ophthalmology 84, n.º 8 (1 de agosto de 2000): 810–12. http://dx.doi.org/10.1136/bjo.84.8.810.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Lee, J. "Preretinal neovascularisation associated with choroidal melanoma". British Journal of Ophthalmology 85, n.º 11 (1 de noviembre de 2001): 1309–12. http://dx.doi.org/10.1136/bjo.85.11.1309.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Aisenbrey, S., F. Gelisken, P. Szurman y K. U. Bartz-Schmidt. "Surgical treatment of peripapillary choroidal neovascularisation". British Journal of Ophthalmology 91, n.º 8 (14 de febrero de 2007): 1027–30. http://dx.doi.org/10.1136/bjo.2006.108118.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Binder, S. "Surgical treatment of peripapillary choroidal neovascularisation". British Journal of Ophthalmology 91, n.º 8 (17 de julio de 2007): 990–91. http://dx.doi.org/10.1136/bjo.2007.114009.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Bradbury, Jane. "Integrin antagonists may prevent retinal neovascularisation". Lancet 347, n.º 9010 (mayo de 1996): 1249. http://dx.doi.org/10.1016/s0140-6736(96)90751-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Gupta, B., S. Parvizi y M. D. Mohamed. "Bietti crystalline dystrophy and choroidal neovascularisation". International Ophthalmology 31, n.º 1 (23 de octubre de 2010): 59–61. http://dx.doi.org/10.1007/s10792-010-9406-8.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!